Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nurix Therapeutics (NRIX) Shares Outstanding (2019 - 2025)

Nurix Therapeutics (NRIX) has disclosed Shares Outstanding for 7 consecutive years, with $101.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 34.19% to $101.8 million in Q4 2025 year-over-year; TTM through Nov 2025 was $101.8 million, a 34.19% increase, with the full-year FY2025 number at $101.8 million, up 34.19% from a year prior.
  • Shares Outstanding was $101.8 million for Q4 2025 at Nurix Therapeutics, up from $76.9 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $101.8 million in Q4 2025 to a low of $39.1 million in Q1 2021.
  • A 5-year average of $56.9 million and a median of $48.1 million in 2023 define the central range for Shares Outstanding.
  • Peak YoY movement for Shares Outstanding: soared 1070.75% in 2021, then rose 1.43% in 2022.
  • Nurix Therapeutics' Shares Outstanding stood at $44.7 million in 2021, then increased by 5.62% to $47.2 million in 2022, then rose by 3.28% to $48.7 million in 2023, then surged by 55.73% to $75.9 million in 2024, then surged by 34.19% to $101.8 million in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Shares Outstanding are $101.8 million (Q4 2025), $76.9 million (Q3 2025), and $76.4 million (Q2 2025).